Volume 16, Issue 2, May 2005
The Targeted & Biological Therapies SIG Newsletter is
underwritten by a grant from Schering-Plough Oncology
     
Coordinator's Message
Get Involved as We Continue to Grow

Paula Muehlbauer, RN, MSN, OCN®
Arlington, VA
pmuehlbauer@cc.nih.gov

Welcome to the newsletter for one of the fastest-growing ONS SIGs. Why do I say this? Our membership has more than doubled since 2002, perhaps because of the increasingly widespread use of targeted and biologic therapies. ONS recognizes the need to equip oncology nurses with the knowledge necessary to care for patients receiving these types of therapies.

Our SIG has been involved actively in sponsoring educational sessions. At the ONS 30th Annual Congress, our SIG sponsored two sessions, a pre-Congress session titled "A Targeted and Biological Therapy Primer: They Keep on Coming and They Are Here to Stay," and an instructional session, "Beyond Fantasy Into Reality: Treatment of Cancer in the Next 10 Years." This fall, we also will be offering a SIG-sponsored, six-hour institute at the 2005 Institutes of Learning November 11–13 in Phoenix, AZ.

 
The Targeted and Biological Therapies SIG Newsletter is produced by members of the
Targeted and Biological Therapies SIG and ONS staff and is not a peer-reviewed publication.

Special Interest Group Newsletter  May 2005
 
   

Coordinator's Message
Get Involved as We Continue to Grow

Paula Muehlbauer, RN, MSN, OCN®
Arlington, VA
pmuehlbauer@cc.nih.gov

Welcome to the newsletter for one of the fastest-growing ONS SIGs. Why do I say this? Our membership has more than doubled since 2002, perhaps because of the increasingly widespread use of targeted and biologic therapies. ONS recognizes the need to equip oncology nurses with the knowledge necessary to care for patients receiving these types of therapies.

Our SIG has been involved actively in sponsoring educational sessions. At the ONS 30th Annual Congress, our SIG sponsored two sessions, a pre-Congress session titled "A Targeted and Biological Therapy Primer: They Keep on Coming and They Are Here to Stay," and an instructional session, "Beyond Fantasy Into Reality: Treatment of Cancer in the Next 10 Years." This fall, we also will be offering a SIG-sponsored, six-hour institute at the 2005 Institutes of Learning November 11–13 in Phoenix, AZ.

On behalf of our SIG, I would like to extend a hearty congratulations to Mary Callaghan, RN, MS, AOCN®, the recipient of the ONS Excellence in Biotherapy Nursing Award. She received this award at Congress in Orlando, FL, and it is well deserved. Do you know an individual who should be nominated for this award next year? If so, an application can be downloaded from the ONS Web site (http://www.ons.org/).

More opportunities will be available soon for you to become involved in our SIG. Some of these opportunities will be apparent after you read our SIG meeting minutes from this year's Congress, which will be found on our SIG Virtual Community. Be sure to look for them. They also will be mentioned in our next newsletter, so stay tuned. Have a good summer!
 
Back to SIG Newsletter front page
 
  
 

Special Interest Group Newsletter  May 2005
 
   

Learn About a Novel Therapy to Treat Non-Hodgkin Lymphoma

Pamela L. Walker, RN, OCN®
Houston, TX
plwalker@mdanderson.org

Targeted therapies such as denileukin diftitox (Ontak®, Ligand Pharmaceuticals, Inc., San Diego, CA) have resulted in potentially significant advances in the treatment of non-Hodgkin lymphoma (NHL). Oncology nurses must possess an understanding of Ontak's unique mechanism of action and its side effects to successfully manage patients being treated with this novel therapy. "Ontak is a genetically engineered fusion protein that directs the lethal action of the diphtheria toxin to cells bearing the IL-2 [interleukin-2] receptors complex on their surfaces" (Walker & Dang, 2004, p. 171): activated T cells, B cells, and monocytes. IL-2 binds to the surface receptors on activated T cells, B cells, and monocytes. "The toxin fragment then is internalized, leading to disruption of protein synthesis and eventual cell death . . . Ontak specifically kills tumor cells expressing the intermediate and high-affinity IL-2 receptors while sparing non-expressing neighboring cells" (Walker & Dang, p. 171). In contrast to conventional chemotherapy, Ontak is not myelosuppressive nor immunosuppressive and is administered at 18 mg/kg per day over 60 minutes for five consecutive days every three weeks. Patients are medicated with corticosteroids, diphenhydramine, and acetaminophen before each infusion of Ontak to reduce and prevent hypersensitivity reactions. The most common drug-related side effects are hypoalbuminemia and elevated transaminases (LFTs); weekly laboratory studies demonstrated that these abnormalities tended to be limited and transient. Treatment should be delayed until albumin levels reach 3 g/dl or higher and LFTs return to a grade 1 level. When treatment is resumed, the dose should be reduced by 50% to 9 mcg/kg per day.

The most common patient-reported side effects with Ontak are fatigue and flu-like symptoms with non-neutropenic fevers. Although fever in treated patients is thought to be drug related, all patients with temperatures greater than 101ºF were screened for occult infections. One-third of patients report skin reactions, including rash and pruritis. To maintain skin integrity, patients should be encouraged to drink liberal amounts of fluids, moisturize their skin, and avoid extremes in temperature by taking tepid baths or showers. Instruct patients to use over-the-counter antihistamines orally and topically for moderate to severe pruritis.

A potentially serious side effect of Ontak is vascular leak syndrome (VLS). VLS is associated with a triad of symptoms: edema, hypoalbuminemia (< 2.8 g/dl), and hypotension. The highest incidence rates of VLS occur with the first cycle of Ontak, and VLS is unlikely to recur with subsequent cycles. Instruct patients to report weight gain greater than five pounds, pedal edema, or dyspnea (Walker & Dang, 2004). Careful medical management is needed to treat VLS, which can be accomplished through weekly laboratory tests and patient assessment. Also, patient education is vital; generally, patients who reported weight gain or edema were treated with a mild diuretic for three to five days.

Ontak is a novel therapy that appears to demonstrate clinical benefit in patients with NHL in ongoing phase II trials at the University of Texas M.D. Anderson Cancer Center. "Ontak is well tolerated and the majority of side effects are transient and diminish in severity with each treatment cycle" (Walker & Dang, 2004, p. 172). This novel therapy requires careful patient education and nursing management to ensure patient safety and optimize treatment benefits.

Reference
Walker, P.L., & Dang, N.H. (2004). Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma. Clinical Journal of Oncology Nursing, 8, 169-174.
 
Back to SIG Newsletter front page
 
  
 

Special Interest Group Newsletter  May 2005
 
   

Do You Wonder Where Drug Names Come From?


Jeannette Y. Wick, RPh, MBA
Arlington, VA
wickj@ctep.nci.nih.gov

Did you ever hear someone else stumble over a new drug name and wonder, "Is that how you say that?" Alvocidib, bevacizumab, cetuximab, defibrotide . . . Pronunciation of the more than 33,000 trademarked names and 9,000 generic names used in the United States (Lambert, Chang, & Lin, 2001) can be tricky. When you examine the method behind the apparent madness, you'll find that generic names are clues about the agent's mechanism of action, and perhaps its source.

First, let's differentiate between nonproprietary (i.e., generic names) and proprietary (i.e., brand names and trademarks) drug lexica. Generic names average 14.4 letters and 5 syllables. Usually, they are more confusing than proprietary names, which average 10.4 letters and 3.53 syllables (Gundersen, 1998).

Generic Jargon
The U.S. Adopted Names (USAN) Council uses strict criteria to develop generic names suitable for multiple settings. A drug or biologic agent's sponsor can suggest a generic name, but if the USAN council considers the suggestion inappropriate, it suggests a new name. The World Health Organization's International Nonproprietary Name Committee is the final approving authority (Gundersen, 1998; U.S. Adopted Names Council, 2005). Lexicon problems can be complex because chosen names may be words in other languages, or even may be offensive.

Because people differentiate similar names by the first few letters, stems of drug names, for instance the "cep-" that plagued the cephalosporin class with errors, have been abandoned. Some current naming restrictions include the following.

  • "Rac-" can be used only for a racemic mixture.
  • "Dex-" and "lev-" can be used only for dextro- [R(+)] or levo- [S(-)] rotating enantiomers.
  • "Ar-" and "es-" are reserved for the R(-) and S(+) isomers of the levorotatory and dextrorotatory forms, respectively.
  • Generics drug names do not begin with the letters H, J, K, or W, because these letters either do not exist in some of the 130 countries that use USANs or have different sounds in various languages.
  • Names do not begin with X and Z because they often sound alike.
  • Stems such as "brev," "vel," and "mal" are not used because of their implications (i.e., brevity, velocity, bad).

United States Adopted Names
The USAN (i.e., the drug name) should be short, easy to pronounce, and euphonic (Wick, 2004). Misleading or confusing sounds or syllables should be avoided.

Names are based on stems (syllables common to agents sharing pharmacologic actions) (Wick, 2004). For example, the stem -tinib refers to tyrosine kinase inhibitors. A list of stems is available at www.ama-assn.org/go/usan.

Example: Monoclonal Antibodies
Monoclonal antibodies (MABs) are one of the lexicon's greatest challenges. Because of the sheer number of drugs, finding simple, informative, and unique names has become increasingly difficult and led to many tongue-twisting names. The USAN council does have a method to bestow names, however, and differences between agents become obvious when you know the system. The suffix "-mab" is used to identify a MAB or fragment (i.e., rituximab). The animal source is identified by a vowel or two-letter pair in the middle of the word (i.e., a = rat, e = hamster, i = primate, o = mouse, u = human, xi = chimera, and zu = humanized). The target disease or condition also is identified within the drug name. "-Vir- is used for viruses, "-bac-" for bacterial, "-lim-" for immune, "-les-" for lesions, "-cir-" for cardiovascular, and "-tu-" for tumor. Therefore, adalimumab is an immunomodulating humanized MAB, rituximab is a chimeric MAB, and trastuzumab is a humanized MAB, with the last two agents used in tumors (Wick, 2004).

You can find similar explanations for erythropoietins, interferons, interleukins, and somatotropins on the USAN Web site at www.ama-assn.org/go/usan.

References
Gundersen, L. (1998). The complex process of naming drugs. Annals of Internal Medicine, 129, 677–678.

Lambert, B.L., Chang, K.Y., & Lin, S.J. (2001). Descriptive analysis of the drug name lexicon. Drug Information Journal, 35, 163–172.

U.S. Adopted Names Council. (2005). United States adopted names. Retrieved April 13, 2005, from http://www.ama-assn.org/go/usan

Wick, J. (2004). What's in a drug name? Journal of the American Pharmacists Association, 44, 12–14.

Bibliography
Aldersey-Williams, H. (1998, May 29). Popping mad. New Statesman, 11(506), 46.

Gertsel, J. (2003, August 22). What's in a name? Elevated drug sales. Retrieved December 20, 2003, from http://www.thestar.com

Igor International. (2005). Taxonomy of biotech and pharmaceutical names. Retrieved April 8, 2005, from http://www.igorinternational.com/processes/biotech-pharmaceutical-name-taxonomy.php

Krauskopf, L. (2002). Naming new drugs: Costly, complex. Retrieved April 13, 2005, from http://www.namebase.com/news_03.html

Lambert, B.L., Chang, K.Y., & Gupta, P. (2003). Effects of frequency and similarity neighborhoods on pharmacists' visual perception of drug names. Social Science and Medicine, 57, 1939–1955.

Message in a bottle: How drug names hook consumers. (2003). Psychology Today, 36, 78.

Miller, D. (2003, January 20). What's in a (drug) name? Drug Topics, 3.

Payton, H. (2002). What's in a name? Retrieved April 8, 2005, from http://www.igorinternational.com/press/bbc-naming-a-product-business.php

Rowland, C. (2003, September 12). Pats ink Levitra marketing deal. Boston Globe, p. D1.

The names of pills matter. (2003, January 18). Economist, 65.
 
Back to SIG Newsletter front page
 
  		 
 

Special Interest Group Newsletter  May 2005
 
   

Editor's Message
Welcome Our New Coeditors

Debbie Parchen, RN, BSN, OCN®
Gaithersburg, MD
dparchen@mail.cc.nih.gov

As I step down as editor of our SIG newsletter, I would like to extend an enormous thank you to three nurses who made a difference to me over these past three years: Ex Officio Peg Esper, MSN, RN, CS, AOCN®, SIG Coordinator Paula Muehlbauer, RN, MSN, OCN®, and previous SIG Editor Mary Callaghan, RN, MS, AOCN®. They were always available when I had a question or needed assistance. This truly is a product that is only as good as the sum of its parts!

Here is another thought that you have heard before but is worth mentioning again. I encourage each and every one of you to step forward and volunteer in some capacity doing whatever interests you. You surely will get more out of the experience than you expect. Being the SIG editor has been a wonderful and rewarding experience for me.

I would like to take this opportunity to introduce our two new coeditors: Victoria Mills, RN, from Atlanta, GA, and Denise Lapka, RN, MS, AOCN®, CNS, from Orland Park, IL. Together, they bring close to 50 years of nursing experience to the position, many of which have been spent working in the targeted and biologic therapies field. Collectively, they have been involved in numerous professional activities, from writing and reviewing manuscripts to research to staff and patient education. They are excited about serving as your new coeditors, and we extend a wholehearted welcome to them.

 
Back to SIG Newsletter front page
 
  
 

Special Interest Group Newsletter  May 2005
 
   

St. John's Wort May Cause Side Effects in Patients Taking Gleevec®


The November 16, 2004, issue of the NCI Cancer Bulletin and the October 2004 issue of Clinical Pharmacology and Therapeutics reported findings from a study conducted by researchers at the University of Florida and the University of Pittsburgh. St. John's wort, an over-the-counter treatment for depression, was found to cause side effects in patients with cancer who are also taking imatinib mesylate (Gleevec® [Novartis Pharamceuticals Corporation, East Hanover, NJ]). This plant derivative was found to increase imatinib metabolism and its removal from the blood by 44%, which weakened the standard and effective dose.
 
Back to SIG Newsletter front page
 
  
 

Special Interest Group Newsletter  May 2005
 
   

Request Interleukin-2 Patient Discharge Education Sheets


Interleukin-2 patient discharge education sheets are available from the Chiron Corporation (Emeryville, CA) in hard copy and as a PDF file. The company is looking into making these sheets available in other forms. To have them mailed to you, contact Pharmaceutical Representative Brendan P. Delaney by e-mail (brendan_delaney@chiron.com), mail (4560 Horton St. U-776, Emeryville, CA 94608-2916), phone (510-923-442), or fax (510-923-6603).
 
Back to SIG Newsletter front page
 
  
 

Special Interest Group Newsletter  May 2005
 
   

Take a Look at These Announcements



ONS Virtual Mentoring Program
ONS is offering a new virtual mentoring program to support the ongoing development of oncology nurses. Whether you're a seasoned oncology nurse, a less experienced nurse, or new to oncology, be sure to take advantage of this valuable opportunity.

As a mentor, you will have the opportunity to strengthen your coaching skills, demonstrate leadership, and contribute to the development of oncology nurses from around the world. We are confident that you will find this to be one of the most rewarding experiences in your professional career. To access the tool and enroll in the program as a mentor, visit www.3creekmentoring.com/ONS and enter group code 921911.

As a mentee, you can expect to expand your personal networking opportunities, have a sounding board for testing your ideas and plans, receive positive and constructive feedback on professional and personal development, and increase your self-awareness and self-discipline. To access the tool and enroll as a mentee, visit www.3creekmentoring.com/ONS and enter group code 789718.

Election Results Are in
ONS is pleased to announce the results of the 2005 ONS Election. Visit www.ons.org/membership/election/index.shtml to get acquainted with your new President-Elect, Directors-at-Large, and Nominating Committee members.

2005 Oncology Nursing Day and Month Kits Are Here
Prepare for the 2005 Oncology Nursing Day and Month celebration from April 28–May 31 with the new Oncology Nursing Month kit from ONS. You can view the contents online or download the entire kit, including the new color poster. Go to www.ons.org/membership/nursemonth.shtml to get started.

Are You New to Oncology?
If so, enroll in the Cancer Basics online course series. This new four-part online series will provide you with a fundamental understanding of cancer care. If you're an experienced cancer professional, this series will serve as a valuable review. For complete information or to register, go to http://onsopcontent.ons.org/education/distanceeducation/cancerbasics/index.shtml.

Check Out the Redesigned Evidence-Based Practice Resource Area
Use the Evidence-Based Practice Resource Area as your guide to identify, critically appraise, and use evidence to solve clinical problems. Be sure to check out the new format, which allows for much easier navigation at http://onsopcontent.ons.org/toolkits/evidence/index.shtml.

Take Advantage of Member-Only Benefits
ONS members automatically receive more than $460 worth of member-only benefits a year . . . that's five times the cost of membership. Encourage others to join and earn rewards through the Member-Bring-a-Member Program. For more information, visit www.ons.org/membership/mbam.shtml.

New Resource for Nurse Managers Coming Soon
Nursing Management: Principles and Practice provides an in-depth review of general and oncology nursing management principles to guide the practice and development of nurse managers. This resource will be available soon but can be ordered now at a discounted price. Go to http://esource.ons.org/ProductDetails.aspx?sku=INPU0553 and reserve your copy today.

Get the Latest in Priority Symptom Management Information
This new series of four Web casts offers timely research insights on topics key to your everyday practice. In addition, you can earn free continuing education credits when you view each Web cast and complete and return your evaluation. Topics include sleep and fatigue in children and adolescents with cancer, computerized symptom and quality-of-life assessment, telephone support interventions, and hot flash physiology in breast cancer. Each Web cast is worth 1.2 contact hours. More information can be found at http://onsopcontent.ons.org/education/Webcasts/prism04/.

New Core Curriculum Available Now
Entirely revised, updated, and expanded to reflect the current state of oncology nursing practice, the new fourth edition of the Core Curriculum for Oncology Nursing is the definitive source for concepts and practices in oncology nursing. Based on the blueprint of the OCN® examination by the Oncology Nursing Certification Corporation), this resource is a powerful study tool for nurses planning to take the OCN® test. Click here to order your copy today.

 
Back to SIG Newsletter front page
 
  
 

Special Interest Group Newsletter  May 2005
 
   

Welcome New Members


The Targeted and Biological SIG welcomes the following new members.

Carrie Barnhart
Sarah Bear
Judith Bikos
Terry Bivona
Delcina Brown
Marcia Boudreaux
Susan Cahoon
Donna Marie Curran
Elizabeth Dennison
Patricia Dunn
Susan Epting
Sarah Evans
Patricia Fischer
Scott Fredericksen
Denise Gallager
Rhodora Garcia
Gerry Gorospe
Cheryl Holesinger
Arlene Hsu
Rosa Keane
Helen Larson
Colleen Lehmann
Georgann Lennon
 Emmanouel Magoulakis
Victoria Mills
Barbara Morollo
Bonnie Murdock
Jackie Nelson
Sam Oltromonto
Beth Peller
Pat Ragsdale
Marita Ripple
Kathleen Roy
Janet Rourke
Kimberly Shiley
Debora Sikich
Linda Simmons
Lisa Starkel
Linda Swanson
Lynn Sweeney
Charles Turner
Debra Wayland
Nancy Wells
Rachel Williams
Leah Wolfe
 
Back to SIG Newsletter front page
 
  
 

Special Interest Group Newsletter  May 2005
 
   

Membership Information

SIG Membership Benefits

  • Network with colleagues in an identified subspecialty area around the country.
  • Contribute articles for your SIG’s newsletter.
  • Participate in discussions with other SIG members.
  • Contribute to the future path of the SIG.
  • Share your expertise.
  • Support and/or mentor a colleague.
  • Receive information about the latest advancements in treatments, clinical trials, etc.
  • Participate in ONS leadership by running for SIG coordinator-elect or join SIG work groups.
  • Acquire information with a click of a mouse at http://sig.ons.wego.net/index.v3page;jsessionid=l5nhe8e4qt77?v2_group=0&p=4918, including
    • Educational opportunities for your subspecialty
    • Education material on practice
    • Calls to action
    • News impacting or affecting your specific SIG
    • Newsletters
    • Communiqués
    • Meeting minutes.
Join a Virtual Community

A great way to stay connected to your SIG is to join its Virtual Community. It’s easy to do so. All you will need to do is
  • Log on to the ONS Web site (www.ons.org/).
  • Select “Membership” from the tabs above.
  • Then, click on “ONS Chapters and Special Interest Groups.”
  • Scroll down to “Visit the ONS Special Interest Groups (SIG) Virtual Community” and click.
  • Now, select “Find a SIG.”
  • Locate and click on the name of your SIG from the list of all ONS SIGs displayed.
  • Once the front page of your SIG's Virtual Community appears on screen, select “New User” from the top left. (This allows you to create log-in credentials.)
  • Type the required information into the text fields as prompted.
  • Click “Join Group” (at the bottom right of the text fields) when done.

    Special Notices
    • If you already have log-in credentials generated from the ONS Web site, use this information instead of attempting to generate new information.
    • If you created log-in credentials for the ONS Web site and wish to have different log-in information, you will not be able to use the same e-mail address to generate your new credentials. Instead, use an alternate e-mail address.
Subscribe to Your SIG’s Virtual Community Discussion Forum

All members are encouraged to participate in their SIG’s discussion forum. This area affords the opportunity for exchange of information between members and nonmembers on topics specific to all oncology subspecialties. Once you have your log-in credentials, you are ready to subscribe to your SIG’s Virtual Community discussion forum. To do so,
  • Select “Log In,” located next to “New User,” and enter your information.
  • Next, click on the “Discussion” tab on the top right of the title bar.
  • Now, select “Featured Discussion” from the left drop-down menu.
  • Locate and select “Subscribe to Discussion” inside the “Featured Discussion” section.
  • Go to “Subscription Options” and select “Options.”
  • When you have selected and entered all required criteria, you will receive a confirmation message.
  • Click “Finish.”
  • You are now ready to begin participating in your SIG’s discussion forum.
Participate in Your SIG’s Virtual Community Discussion Forum
  • First, log in. (This allows others to identify you and enables you to receive notification [via e-mail] each time a response or new topic is posted.)
  • Click on “Discussion” from the top title bar.
  • Select “Featured Discussion” from the left drop-down menu.
  • Click on any posted topic to view contents and post responses.
Sign Up to Receive Your SIG’s Virtual Community Announcements

As an added feature, members also are able to register to receive their SIG’s announcements by e-mail.
  • From your SIG’s Virtual Community page, locate the “Sign Up Here to Receive Your SIG’s Announcements” section. This appears above the posted announcements section.
  • Select the “Click Here” feature, which will take you to a link to subscribe.
  • Once the “For Announcement Subscription Only” page appears on screen, select how you wish to receive your announcements.
    • As individual e-mails each time a new announcement is posted
    • One e-mail per day comprised of all new daily announcements posted
    • Opt-out, indicating that you will frequently browse your SIG’s Virtual Community page for new postings
  • Enter your e-mail address.
  • Click on “Next Page.”
  • Because you have already joined your SIG’s Virtual Community, you will receive a security prompt with your registered user name already listed. Enter your password at this prompt and click “Finish.”
  • This will bring up a listing of your SIG’s posted announcements. Click on “My SIG’s Page” to view all postings in their entirety or to conclude the registration process and begin browsing.
 
Back to SIG Newsletter front page
 
  
 

Special Interest Group Newsletter  May 2005
 
   

Targeted and Biological Therapies SIG Officers

Coordinator
Paula Muehlbauer, RN, MSN, OCN®
1160 N. Vernon St.
Arlington, VA 22201-5757
703-243-6362 (H)
pmuehlbauer@cc.nih.gov

Editor
Debbie Parchen, RN, BSN, OCN®
23828 Rolling Fork Way
Gaithersburg, MD 20882-2725
301-253-1701 (H)
dparchen@mail.cc.nih.gov

Coeditor
Denise Lapka, RN, MS, AOCN®, CNS
18051 Arthur Dr.
Orland Park, IL 60467-8428
708-478-1978 (H)
lapka.denise@gene.com

 

Coeditor
Victoria Mills, RN
430 W. Spalding Dr. NE
Atlanta, GA 30328-1919
770-804-8681 (H)
404-712-4169 (fax)
victoriamariemills@yahoo.com

ONS Publishing Division Staff
Jacqueline Moore, BA
Copy Editor
412-859-6322
jmoore@ons.org

Know someone who would like to receive a print copy of this newsletter?
To print a copy of this newsletter from your home or office computer, click here or on the printer icon located on the SIG Newsletter front page. Print copies of each online SIG newsletter also are available through the ONS National Office. To have a copy mailed to you or another SIG member, contact Membership/Leadership Administrative Assistant Carol DeMarco at cdemarco@ons.org or 866-257-4ONS, ext. 6230.

To view past newsletters click here.

ONS Membership/Leadership Team Contact Information

Angie Stengel, Director of Membership/Leadership
astengel@ons.org
412-859-6244

Diane Scheuring, Manager of Member Services
dscheuring@ons.org
412-859-6256

Carol DeMarco, Membership/Leadership Administrative Assistant
cdemarco@ons.org
412-859-6230

The Oncology Nursing Society (ONS) does not assume responsibility for the opinions expressed and information provided by authors or by Special Interest Groups (SIGs). Acceptance of advertising or corporate support does not indicate or imply endorsement of the company or its products by ONS or the SIG. Web sites listed in the SIG newsletters are provided for information only. Hosts are responsible for their own content and availability.

Oncology Nursing Society
125 Enterprise Dr.
Pittsburgh, PA 15275-1214
866-257-4ONS
412-859-6100
http://www.ons.org/

 
Back to SIG Newsletter front page